Ceftriaxone in the Management of Bipolar Depression

Last updated: March 27, 2020
Sponsor: Yale University
Overall Status: Terminated

Phase

N/A

Condition

Depression

Depression (Major/severe)

Bipolar Disorder

Treatment

N/A

Clinical Study ID

NCT00566111
0704002567
  • Ages 18-65
  • All Genders

Study Summary

We aim to study the efficacy of intravenous ceftriaxone in a four-week, inpatient, placebo-controlled, double-blind study, as an augmentation therapy in patients with bipolar disorder, currently depressed, who have failed to respond to conventional treatments.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • DSM-IV diagnosis of bipolar disorder

  • Presence of a current major depressive episode on the SCID

  • Score of 17 or greater on the HDRS

  • Failure to respond to two previous medication trials

  • Capable of giving voluntary written consent

Exclusion

Exclusion Criteria:

  • Hypersensitivity to penicillin or cephalosporin, resulting in anaphylaxis

  • Significant current substance dependence/abuse within 3 months preceding the trial

  • Significant history of intravenous drug abuse

  • Active suicidal ideation

  • Pregnant/lactating mothers

  • Significant medical history

  • Patients on anticoagulation treatment

  • Patients who test positive for HIV or Hep B or C

Study Design

Total Participants: 5
Study Start date:
September 01, 2007
Estimated Completion Date:
December 31, 2009

Connect with a study center

  • Yale University School of Medicine

    New Haven, Connecticut 06519
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.